Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Leukemia, Myeloid, Acute 4Primary Myelofibrosis 3Neoplasms 3Recurrence 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Lymphoma 2Leukemia, B-Cell 2Leukemia 2Thrombocythemia, Essential 1Sezary Syndrome 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myelomonocytic, Chronic 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 87fludarabine 77fludarabine phosphate 45Tacrolimus 45Whole-Body Irradiation 42Mycophenolic Acid 42Busulfan 35Melphalan 32Antilymphocyte Serum 24Methotrexate 23thymoglobulin 22Standard of Care 22Rituximab 22venetoclax 20Thiotepa 20Sirolimus 20Azacitidine 20Stem Cell Transplantation 18Granulocyte Colony-Stimulating Factor 18Practice Guidelines as Topic 17Cytarabine 16Bortezomib 16Nivolumab 15Filgrastim 15Specimen Handling 14Dexamethasone 14Blood Specimen Collection 14Cyclosporine 13Surveys and Questionnaires 12Mesna 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × navitoclax × Other hematologic neoplasm × Clear all
NCT00788684 2025-02-20

Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers

AbbVie

Phase 1 Completed
29 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡